Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 19/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638006 | 0.87 | AAK1 (1.00) | AAK1EGFRFLT1FLT4KDR | |
| SCHEMBL16635587 | 0.85 | AAK1 (1.00) | AAK1EGFRFLT1FLT4KDR | |
| SCHEMBL20184198 | 0.73 | AAK1 (0.79) | AAK1 | |
| SCHEMBL16636896 | 0.72 | AAK1 (1.00) | AAK1EGFRKDR | |
| SCHEMBL16636115 | 0.72 | AAK1 (1.00) | AAK1EGFRKDR | |
| SCHEMBL16636472 | 0.70 | AAK1 (1.00) | AAK1EGFRKDR | |
| SCHEMBL16635635 | 0.70 | AAK1 (1.00) | AAK1EGFR | |
| SCHEMBL16636166 | 0.70 | AAK1 (1.00) | AAK1 | |
| SCHEMBL16636920 | 0.70 | AAK1 (1.00) | AAK1EGFR | |
| SCHEMBL16635946 | 0.69 | AAK1 (1.00) | AAK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | claimed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | claimed |
| EP-3054955-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-08-17 | — | — | EP | claimed |
| WO-2015054358-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | claimed |
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015054358-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | AAK1, DAPK2, DAPK1 | AAK1 1/4885EGFR 2422/4885FLT1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.